New Year, New Drug Price Reporting Bills

2024 was a record-setting year for new State Drug Price Transparency Reporting (SPTR) requirements.  From California to New Jersey, North Dakota to Texas, Maine to New Mexico, Washington to Florida, we've seen new SPTR laws enacted in every area of the country and across the political spectrum.

But brace yourselves because 2025 is picking up right where we left off.  In fact, while we are just a few days into the new year, we already have one of our first bills in New York that is proposing new SPTR requirements (in addition to the NY law that was already enacted last year)!

Already managing perpetual SPTR requirements in 15+ states with 30+ price increase calculations (not to mention new drug notifications and similar reporting ) is enough to make your head spin.  To alleviate this burden and help avoid potential regulatory scrutiny by exceeding price increase thresholds (not to mention severe enforcement penalties which have already been levied against the industry), our clients have trusted our cost-effective reporting services and first-of-its-kind software platform, Rx Price Transparency Tracker, which provides instant analysis on drug pricing considerations and their regulatory impact.

We've started this blog to help keep the industry informed of SPTR (and Spend Transparency) reporting requirements.

Keep checking back for more updates.  In the meantime, we hope you had no issues submitting the Louisiana SPTR report and have submitted or are about to submit the other January SPTR reports, such as North Dakota, Texas, West Virginia, Maine, Pennsylvania, and California.  Good luck!